Research Reports

Key takeaways

Operating loss improved 28.7% YoY to -$3.4M from -$4.8M, reflecting better expense management.

Net loss narrowed 26.6% to -$3.3M from -$4.5M, driven by operational efficiencies.

Diluted EPS improved 28.6% to -$0.30 from -$0.42, due to reduced per-share losses.

Operating cash use decreased to -$3.8M in free cash flow, indicating moderated burn.

Management anticipates expenses will increase substantially to complete clinical trials, requiring additional funding.

Full analysis

Lantern Pharma Inc. (LTRN), an AI-focused oncology company, reported narrowed losses for Q1 FY2026 ending March 31, 2026, primarily due to cost discipline amid ongoing drug development. Operating income loss improved 28.7% year-over-year to -$3.4 million from -$4.8 million in Q1 FY2025, as the company managed expenses while advancing its pipeline. This progress reflects operational efficiencies in a no-revenue environment dedicated to transforming oncology drug discovery through AI, including therapies like LP-300, LP-184/STAR-001, LP-284, and preclinical ADC efforts powered by modules improving precision, cost, and timelines.

LTRN · Lantern Pharma Inc.

Summary

Key takeaways

Full analysis